HOUSTON, Texas, May 19, 2026
Oorja Bio announced positive first-in-human Phase 1 clinical data for ORJ-001, a first-in-class peptide therapeutic designed to treat idiopathic pulmonary fibrosis (IPF) by targeting alveolar epithelial type 2 (AEC2) cells. The data, presented at the American Thoracic Society (ATS) 2026 International Conference in Orlando, demonstrated that ORJ-001 achieved therapeutically relevant exposure and was generally well tolerated in healthy volunteers, supporting the company’s plans to initiate a Phase 2 clinical trial in IPF patients later this year. In parallel, preclinical studies presented at the conference showed durable lung tissue target engagement, biomarker improvements, and evidence of fibrosis reversal, strengthening the case for ORJ-001 as a potentially disease-modifying therapy in pulmonary fibrosis. The findings position Oorja Bio among the emerging biotechnology companies advancing regenerative approaches for chronic fibrotic lung diseases with high unmet medical need.
ORJ-001 Targets AEC2 Cells to Restore Lung Repair Mechanisms
Unlike currently approved IPF therapies that mainly slow disease progression, ORJ-001 is designed to directly restore the function of AEC2 cells, which play a central role in maintaining and repairing the lung epithelium after injury. The investigational therapy acts as a β1 integrin agonist, activating pathways involved in epithelial regeneration, alveolar repair, and reduction of inflammatory and fibrotic signaling. According to Oorja Bio, this mechanism has the potential to both halt progression of fibrosis and stimulate tissue repair within damaged lungs. The company highlighted that impaired AEC2 regeneration is increasingly recognized as a major biological driver of IPF progression, making AEC2 restoration a promising therapeutic strategy.
The Phase 1 clinical program included two randomized, double-blind, placebo-controlled studies involving a total of 64 healthy volunteers across single-ascending dose (SAD) and multiple-ascending dose (MAD) cohorts. ORJ-001 was administered through subcutaneous injection either daily or weekly. The primary objective focused on safety and tolerability, while secondary objectives evaluated pharmacokinetics and active dose exposure. Results showed no systemic toxicities, with injection-site reactions representing the most common adverse events and remaining mostly mild in severity. Physiologically based pharmacokinetic modeling further confirmed that plasma concentrations achieved in humans were within the pharmacologically active exposure range previously identified in animal studies. These findings provide important validation for advancing ORJ-001 into mid-stage patient studies in IPF.
Preclinical Studies Show Fibrosis Reversal and Biomarker Improvement
Oorja Bio also presented multiple preclinical findings from therapeutic bleomycin-induced lung fibrosis models, widely considered one of the most validated experimental systems for pulmonary fibrosis research. In these studies, ORJ-001 demonstrated durable target tissue engagement lasting up to seven days following a single subcutaneous dose, supporting its potential for practical dosing schedules in future clinical development. Researchers additionally observed declining levels of Tenascin-C (TNC) and Surfactant Protein-D (SP-D) after repeated dosing. TNC is associated with tissue remodeling, chronic inflammation, and fibrosis, while SP-D is a recognized biomarker of AEC2 cell injury. Both biomarkers are linked to long-term outcomes in IPF patients and are currently being evaluated by the U.S. Food and Drug Administration as part of an IPF biomarker scoring system.
Advertisement
Additional preclinical studies presented previously at the Pulmonary Fibrosis Foundation Summit showed that ORJ-001 not only slowed fibrosis progression but also induced reversal of established fibrosis and regeneration of normal lung structure. Researchers reported re-epithelialization of alveolar tissue and restoration of normal alveolar morphology using markers associated with mature alveolar epithelial type 1 (AEC1) cells. According to Oorja Bio Chief Medical Officer Dr. Janethe Pena, ORJ-001 produced significantly better preclinical outcomes compared with currently approved IPF therapies including nintedanib and pirfenidone. If these regenerative and anti-fibrotic effects translate into human efficacy studies, ORJ-001 could represent a major advancement in IPF treatment by addressing the underlying biology of lung tissue repair rather than only slowing functional decline.
Source: Oorja Bio press release
